Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America
TORONTO--(BUSINESS WIRE)--Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), today announced the approval of Cationorm® Plus by Health Canada. Cationorm® Plus is a unique hydrating artificial tear that restores moisture in the eye to provide long-lasting relief for dry eye and ocular allergy symptoms.
For the second time in 15 months, Japanese ophthalmology specialist Santen has earned an FDA approval for its eye drops.
EMERYVILLE, Calif. & UBE, Japan--(BUSINESS WIRE)--Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) today announced that the U.S. Food and Drug Administration (FDA) has approved OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. The approval date was September 22.
Santen has announced the launch of Ducressa in the UK and Ireland. The therapy is a fixed dose combination of levofloxacin and dexamethasone for use after cataract surgery.
EMERYVILLE, Calif.--(BUSINESS WIRE)--Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on eye care, today announced that Verkazia® (cyclosporine ophthalmic emulsion) 0.1% is now available in the United States for the treatment of vernal keratoconjunctivitis (VKC), a rare and recurrent allergic eye condition that causes severe inflammation of the surface of the eye. Verkazia – which is administered as an eye drop – is the first and only FDA-approved topical immunomodulator (drug that suppresses the immune system) for the treatment of VKC in children and adults.
DURHAM, N.C.--(BUSINESS WIRE)--Dec. 7, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopressa®/Rhokiinsa® (netarsudil ophthalmic solution) 0.02% and Rocklatan®/Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The expanded collaboration includes Europe, Commonwealth of Independent States (CIS) countries, China, India, parts of Latin America and the Oceania countries.
Retail-level recall of one batch of Ikervis Eye Drops, Emulsion 1mg/ml, containing ciclosporin, due to a manufacturing issue that may result in the eye drop being less effective.
Santen and Sydnexis execute an exclusive licensing agreement for SYD-101, a
Santen and Sydnexis execute an exclusive licensing agreement for SYD-101, a